These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19339647)

  • 1. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.
    Bostwick JM; Hecksel KA; Stevens SR; Bower JH; Ahlskog JE
    Mayo Clin Proc; 2009 Apr; 84(4):310-6. PubMed ID: 19339647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.
    Hassan A; Bower JH; Kumar N; Matsumoto JY; Fealey RD; Josephs KA; Ahlskog JE
    Parkinsonism Relat Disord; 2011 May; 17(4):260-4. PubMed ID: 21310646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    Moore TJ; Glenmullen J; Mattison DR
    JAMA Intern Med; 2014 Dec; 174(12):1930-3. PubMed ID: 25329919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
    Ahlskog JE
    Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists.
    Singh A; Kandimala G; Dewey RB; O'Suilleabhain P
    J Clin Neurosci; 2007 Dec; 14(12):1178-81. PubMed ID: 17720504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
    Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
    Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.
    Kolla BP; Mansukhani MP; Barraza R; Bostwick JM
    Psychosomatics; 2010; 51(3):271-3. PubMed ID: 20484726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonist: pathological gambling and hypersexuality.
    Prescrire Int; 2008 Oct; 17(97):200-1. PubMed ID: 19536937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
    Pignatti R; Brioschi A; Mauro A; Zamarian L; Wenter J; Semenza C
    Neurocase; 2012; 18(6):503-13. PubMed ID: 22224448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compulsive behaviors in patients with Parkinson's disease.
    Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E
    Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compulsive eating and weight gain related to dopamine agonist use.
    Nirenberg MJ; Waters C
    Mov Disord; 2006 Apr; 21(4):524-9. PubMed ID: 16261618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia.
    Holman AJ
    J Gambl Stud; 2009 Sep; 25(3):425-31. PubMed ID: 19241148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    Klos KJ; Bower JH; Josephs KA; Matsumoto JY; Ahlskog JE
    Parkinsonism Relat Disord; 2005 Sep; 11(6):381-6. PubMed ID: 16109498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased frequency and range of sexual behavior in a patient with Parkinson's disease after use of pramipexole: a case report.
    Munhoz RP; Fabiani G; Becker N; Teive HAG
    J Sex Med; 2009 Apr; 6(4):1177-1180. PubMed ID: 18466265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
    Kumru H; Iranzo A; Carrasco E; Valldeoriola F; Marti MJ; Santamaria J; Tolosa E
    Sleep; 2008 Oct; 31(10):1418-21. PubMed ID: 18853939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
    Bienfait KL; Menza M; Mark MH; Dobkin RD
    J Clin Neurosci; 2010 Apr; 17(4):539-40. PubMed ID: 20171891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.